Journal
EUROPEAN JOURNAL OF IMMUNOLOGY
Volume 49, Issue 8, Pages 1147-1152Publisher
WILEY
DOI: 10.1002/eji.201848058
Keywords
cancer; checkpoint inhibitors; immunotherapy; metabolism; T cells; tumor microenvironment
Categories
Funding
- Cancer Research UK [23269]
- University of Leeds PhD scholarship
Ask authors/readers for more resources
The successful implementation of immunotherapies has provided new impetus in the fight against cancer. Antibody-mediated blockade of immune checkpoint molecules PD-1/PD-L1 and CTLA-4 has had a dramatic impact upon the treatment of previously intractable cancers such as malignant melanoma, while adoptive cell therapies using chimeric antigen receptor-bearing T cells have proven highly efficacious in B cell leukemia. Furthermore, significant progress has been made in understanding the mechanisms by which tumors evade or become resistant to these immunotherapies. In this regard, approaches to broaden the applicability and enhance the efficacy of immunotherapies increasingly include modulation of tumor and immune cell metabolism. In this mini-review, we highlight the most recent studies describing novel approaches and targets for the manipulation of the tumor microenvironment and T cell metabolism and describe how these approaches are being combined with current immunotherapies in preclinical studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available